Targeting MCL-1 in cancer: promise, pitfalls, and the path forward

Q: What does this research mean for the field?

Targeting MCL-1 in cancer shows strong preclinical promise, and ongoing clinical trials evaluating inhibitors like S64315 are critical for translating these findings into effective therapies while navigating associated clinical pitfalls. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Aloke Sarkar; Natalia Timofeeva; Varsha Gandhi

doi:10.1080/10428194.2026.2723846

September 6, 2026Leukemia & lymphoma/Leukemia and lymphoma

Targeting MCL-1 in cancer: promise, pitfalls, and the path forward

View at Publisher

Ask AI

Bookmark

Share

Key Points

Assess the clinical development, therapeutic efficacy, and translational hurdles of targeting the anti-apoptotic protein MCL-1 in cancer using the inhibitor S64315.
Evaluated early-phase clinical trial evidence investigating the selective MCL-1 inhibitor S64315.
Synthesized preclinical validation studies and preliminary clinical outcomes across targeted cancer indications.
Inhibition of MCL-1 shows potent pro-apoptotic activity across preclinical oncology models.
Clinical application of S64315 marks a critical milestone for translating targeted cell-death therapies despite emerging safety and resistance pitfalls.

Implication

Clinical review highlights the therapeutic potential of MCL-1 inhibitor S64315 in oncology, indicating vital opportunities alongside emerging translation challenges.

Abstract

The current clinical trial evaluating the MCL-1 inhibitor (MCL-1i) S64315 represents an important step in translating preclinical findings into the clinic [1]. While MCL-1 inhibition showed strong ...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sarkar et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd75858e84d0ff5b45e16 https://doi.org/10.1080/10428194.2026.2723846

View at Publisher

Ask AI

Bookmark

Share

Targeting MCL-1 in cancer: promise, pitfalls, and the path forward

Key Points

Implication

Abstract

Discussion

Cite This Study

Targeting MCL-1 in cancer: promise, pitfalls, and the path forward

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading